/C O R R E C T I O N - Edgewise Therapeutics/
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
Why Edgewise Therapeutics Stock Is In Focus After Phase 3 Filing For Heart Drug
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $51
Edgewise Therapeutics Says Edgewise Has Submitted STRATUS-HCM Phase 3 Protocol Following End-Of-Phase 2 Meeting
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
Edgewise Therapeutics Q3 Adj. EPS $(0.19) Misses $2.48 Estimate
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics' Investors Focused on Upcoming Phase 3 Design for '7500 in Hypertrophic Cardiomyopathy, RBC Says
William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating
Does Edgewise Therapeutics’ (EWTX) HFpEF Expansion Quietly Redefine Its Core Cardiovascular Strategy?
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
Edgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?
Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - Slideshow
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.